Report
Valens Research

WBA - Embedded Expectations Analysis - 2020 08 20

Walgreens Boots Alliance, Inc. (WBA:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with an 18.2x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may have concerns about their gross margin, script and transaction growth, and omnichannel product and convenience services demand

Specifically, management may lack confidence in their ability to sustain adjusted retail gross margin, improve script growth, and sustain adjusted operating income. They may also be overstating the position of their online business in the U.K., and they may have concerns about the potential of their neighborhood destination concept and the sustainability of government contributions and capex. Moreover, they may lack confidence in their ability to sustain transaction growth and Find Care platform traffic. Management may also have concerns about the continued slowdown in the high street segment, the sustainability of omnichannel product and convenience services demand, and costs of increasing inventory levels. In addition, they may lack confidence in their ability to keep their stores functional, improve their Transformational Cost Management Program, and continue reducing costs
Underlying
Walgreens Boots Alliance Inc

Walgreens Boots Alliance is a holding company. Through its subsidiaries, the company is engaged in retail and wholesale pharmacy. The company's operations are organized into three divisions, which are also its reportable segments: Retail Pharmacy USA; Retail Pharmacy International; and Pharmaceutical Wholesale. The Retail Pharmacy USA division has pharmacy-led health and beauty retail offerings. The Retail Pharmacy International division has pharmacy-led health and beauty retail businesses. The Pharmaceutical Wholesale division, which mainly operates under the Alliance Healthcare brand, supplies medicines, other healthcare products and related services to pharmacies, doctors, health centers and hospitals.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch